Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer

BACKGROUND: There are no established predictive biomarkers for the effectiveness of first-line atezolizumab plus carboplatin and etoposide therapy in patients with small-cell lung cancer (SCLC). Therefore, the current study aimed to investigate whether the Glasgow prognostic score (GPS), neutrophil-...

Descripción completa

Detalles Bibliográficos
Autores principales: Wasamoto, Satoshi, Imai, Hisao, Tsuda, Takeshi, Nagai, Yoshiaki, Minemura, Hiroyuki, Yamada, Yutaka, Umeda, Yukihiro, Kishikawa, Takayuki, Shiono, Ayako, Kozu, Yuki, Shiihara, Jun, Yamaguchi, Ou, Mouri, Atsuto, Kaira, Kyoichi, Kanazawa, Kenya, Taniguchi, Hirokazu, Kaburagi, Takayuki, Minato, Koichi, Kagamu, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895374/
https://www.ncbi.nlm.nih.gov/pubmed/36741711
http://dx.doi.org/10.3389/fonc.2022.1080729

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895374/
https://www.ncbi.nlm.nih.gov/pubmed/36741711
http://dx.doi.org/10.3389/fonc.2022.1080729

Ejemplares similares